Sinclair's study is the first time this technology has been used in humans
Important Considerations While these peptides are generally well tolerated, it is important to approach any therapeutic protocol with proper guidance
It is estimated that up to 50% of people with vEDS are the first in their family to have it because of a random mutation
BPC-157, TB-500, KPV, GHK-Cu 80mg (Klow Blend) $395,00 PRODUCT SHORT DESCRIPTION The BPC-157, TB-500, KPV, and GHK-Cu Klow Blend delivers an advanced, multi-pathway 80mg (80,000mcg) research matrix combining four synergistic synthetic peptides in a single vial
Brand may vary from order to order and variation to variation
Easy measuring: At 4 mg/mL total, 1 unit = 0.01 mL = 40 mcg total (20 mcg AOD + 10 mcg CJC + 10 mcg Ip)